The launch of Index Ventures’ new life sciences fund on March 21st is another big step in the reincarnation of the biotech investment model. As a smaller, focused fund it will carry even further the “asset-centric” strategy Index have championed. But the most obvious new feature is the inclusion of two global pharmaceutical giants as strategic investors in the fund.
It is, therefore, a very different beast from most venture capital funds, particularly in the US. Different doesn’t always mean better, so DrugBaron asks what would be the optimal parameters for a life sciences fund to have in 2012, and measures this new entrant against that yardstick
The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services. The Cambridge Partnership was founded in 2012 to fill a gap. Running a biotechnology company has little …
